Raymond James Downgrades BridgeBio Pharma to Market Perform

BridgeBio Pharma

BridgeBio Pharma

BBIO

0.00

Raymond James analyst Martin Auster downgrades BridgeBio Pharma (NASDAQ: BBIO) from Outperform to Market Perform.